Drug Pricing Response: The 1,000-Day Report
HHS’ “First 100 Days” take on the drug pricing “Blueprint” is a novel use of a tried-and-true milestone for presidential action. But it is probably more enlightening to look at what has happened in the 1,000 days since drug pricing became the overwhelming focus of political attention.
You may also be interested in...
Outgoing BIO CEO Focuses On Out-Of-Pocket Costs As Solution To Drug Pricing Woes
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.
The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant
Those “massive” price cuts US President Trump said would be announced this week? Never mind.
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.